Skip to content

The Respiratory Syncytial Virus Hospitalization Surveillance Network Pilot in Japan

The Respiratory Syncytial Virus Hospitalization Surveillance Network Pilot in Japan - RSV-NET Japan Pilot

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1030230666
Enrollment
500
Registered
2024-02-29
Start date
2024-04-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory infections

Interventions

None listed

Sponsors

Tajima Kentaro
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply: -Aged >- 50 years at onset of hospitalized ARI. -Hospitalized patients with two or more symptoms/signs of an ARI that meet the ARI definitions (see Section 6.1) lasting more than 12 hours -Patients agree to provide nasal/throat swab samples to detect RSV by multiplex-nested PCR and a combination RAT -Participants who are able to provide written IC. If a participant is unable to provide the IC at the time of Day1, a legal representative (family member who live together with the participant) can provide written IC on their behalf. In case of a legal representative will provide, a consent form can be provided remotely via an electronic form.

Exclusion criteria

Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: Hospitalized ARI participants -Re-enrolment if new ARI symptoms/signs are reported within 14 days from the study conclusion contact of the previous ARI. -Participants' ARI symptoms/signs are attributed to aspiration pneumonia diagnosed. -Participant who does not have a digital device such as a smartphone, computer or tablet -Participant is deemed to be ineligible for the study for any other reason by the investigator or sub investigator, eg. cognitive dysfunction, symptom severity that they cannot follow the procedures for study participation.

Design outcomes

Primary

MeasureTime frame
To evaluate operational system for RSV-NET Japan surveillance

Secondary

MeasureTime frame
To describe positivity rate, trend, clinical symptoms/signs, complication of RSV-ARI or other respiratory virus/bacteria in hospitalized ARI participants by site, age group, comorbidity and overall.

Contacts

Public ContactKentaro Tajima

GlaxoSmithKline K.K.

jp.gskjrct@gsk.com+81-120-561-007

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026